339 related articles for article (PubMed ID: 34884494)
1. Crosstalk between Sodium-Glucose Cotransporter Inhibitors and Sodium-Hydrogen Exchanger 1 and 3 in Cardiometabolic Diseases.
Al-Shamasi AA; Elkaffash R; Mohamed M; Rayan M; Al-Khater D; Gadeau AP; Ahmed R; Hasan A; Eldassouki H; Yalcin HC; Abdul-Ghani M; Mraiche F
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884494
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
3. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
McCullough PA; Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Kluger SL; Rangaswami J
Rev Cardiovasc Med; 2018 Jun; 19(2):51-63. PubMed ID: 31032603
[TBL] [Abstract][Full Text] [Related]
5. Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: focus on the mechanisms.
Huang K; Luo X; Liao B; Li G; Feng J
Cardiovasc Diabetol; 2023 Apr; 22(1):86. PubMed ID: 37055837
[TBL] [Abstract][Full Text] [Related]
6. Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy.
Arow M; Waldman M; Yadin D; Nudelman V; Shainberg A; Abraham NG; Freimark D; Kornowski R; Aravot D; Hochhauser E; Arad M
Cardiovasc Diabetol; 2020 Jan; 19(1):7. PubMed ID: 31924211
[TBL] [Abstract][Full Text] [Related]
7. Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure: Proposal of a Novel Mechanism of Action.
Packer M; Anker SD; Butler J; Filippatos G; Zannad F
JAMA Cardiol; 2017 Sep; 2(9):1025-1029. PubMed ID: 28768320
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction.
Liu B; Wang Y; Zhang Y; Yan B
Curr Top Med Chem; 2019; 19(20):1818-1849. PubMed ID: 31456521
[TBL] [Abstract][Full Text] [Related]
9. Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
Packer M
Circulation; 2017 Oct; 136(16):1548-1559. PubMed ID: 29038209
[TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
[TBL] [Abstract][Full Text] [Related]
11. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
12. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
13. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors.
Mordi IR; Lang CC
Heart Fail Clin; 2022 Oct; 18(4):529-538. PubMed ID: 36216483
[TBL] [Abstract][Full Text] [Related]
14. Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts.
Marfella R; D'Onofrio N; Trotta MC; Sardu C; Scisciola L; Amarelli C; Balestrieri ML; Grimaldi V; Mansueto G; Esposito S; D'Amico M; Golino P; Signoriello G; De Feo M; Maiello C; Napoli C; Paolisso G
Metabolism; 2022 Feb; 127():154936. PubMed ID: 34801581
[TBL] [Abstract][Full Text] [Related]
15. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
16. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
Kale A; Sharma A; Anders HJ; Gaikwad AB
Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Older Patients in Routine Clinical Care With or Without History of Atherosclerotic Cardiovascular Diseases or Heart Failure.
Htoo PT; Buse J; Cavender M; Wang T; Pate V; Edwards J; Stürmer T
J Am Heart Assoc; 2022 Feb; 11(4):e022376. PubMed ID: 35132865
[TBL] [Abstract][Full Text] [Related]
18. Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na
Baker HE; Tune JD; Mather KJ; Blaettner BS; Clark HE; Li F; Li X; Kowala MC; Fliegel L; Goodwill AG
Int J Cardiol; 2022 Sep; 363():138-148. PubMed ID: 35753619
[TBL] [Abstract][Full Text] [Related]
19. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
[TBL] [Abstract][Full Text] [Related]
20. mTORC1 and SGLT2 Inhibitors-A Therapeutic Perspective for Diabetic Cardiomyopathy.
Saha S; Fang X; Green CD; Das A
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
